GAITHERSBURG, Md., May 5, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq:OPGN) today announced the pricing of its initial public offering of 2,850,000 units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, at a combined price to the public of $6.00 per unit. All of the units are being offered by OpGen. OpGen's common stock and warrants have been approved for listing on the NASDAQ Capital Market. The units will immediately and automatically separate upon issuance, and each of the common stock and warrants are expected to begin trading separately today, under the symbols "OPGN" and "OPGNW," respectively. Each warrant will be immediately exercisable upon issuance for one share of common stock at an exercise price of $6.60 per share and will expire on May 8, 2020.
OpGen has granted the underwriters the right to purchase up to an additional 427,500 shares of common stock at a price of $5.99 per share and/or 427,500 additional warrants at a price of $0.01 per warrant less, in each case, the applicable underwriting discount, within 45 days from the date of this prospectus to cover over-allotments, if any.
Maxim Group LLC is acting as sole book-running manager and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (Nasdaq:NHLD), is acting as co-manager of the offering.
A registration statement on Form S-1 relating to these securities was declared effective by the Securities and Exchange Commission on May 4, 2015. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Maxim Group LLC, 405 Lexington Ave., 2nd Floor, New York, NY, 10174; by telephone at (800) 724-0761. Copies of the final prospectus relating to the offering may also be obtained on the Securities and Exchange Commission's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
OpGen, Inc. is an early commercial stage company using molecular testing and bioinformatics to assist healthcare providers to combat multi-drug resistant bacterial infections. The company's products and services are designed to enable the rapid identification of hospital patients who are colonized or infected with life-threatening, multi-drug resistant organisms, or MDROs. The company's lead product is the Acuitas® MDRO Gene Test. Products in development include the Acuitas Lighthouse™ MDRO Management System and the Acuitas Resistome Test. In addition, the company has more than 10 years of experience mapping microbial, plant and human genomes. Learn more at www.opgen.com.
CONTACT: OpGen Michael Farmer Director, Marketing (240) 813-1284 email@example.com InvestorRelations@opgen.com Investors LHA Kim Sutton Golodetz (212) 838-3777 firstname.lastname@example.org or Bruce Voss (310) 691-7100 email@example.com Media Lisa Guiterman (301) 217-9353 firstname.lastname@example.orgSource:OpGen, Inc.